Clinical Trial Update: Kinetics, Efficacy and Safety of C1-Esteraseremmer-N [Phase 2]

View source ↗

Summary

Phase 2 trial results for C1-Esteraseremmer-N assess kinetics, efficacy, and safety in hereditary angioedema. The study is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioedema
• Hereditary Angioedema

Drugs mentioned

• C1-Esteraseremmer-N

Snippet

Sponsor: Prothya Biosolutions | Conditions: Hereditary Angioedema Type I, Angioneurotic Edema | Phase 2 | Status: COMPLETED